MCP Showcase
Resmetirom evidence snapshot
Name a drug asset; get a one-page PDF evidence snapshot — regulatory status, pivotal trials, grounded efficacy figures and the trial↔paper link — every number verbatim from Amass.
New to Amass? Connect Amass to Claude first
The prompt
Paste this into Claude
resmetiromDRUG ASSET: resmetirom
You have the Amass MCP connected (TrialCore + BioMedCore). Produce a one-page EVIDENCE SNAPSHOT
PDF for this asset — every figure traceable to an Amass record.
1. STATUS + PIVOTAL TRIALS. Call search_amass_trialcore_records with:
query = the DRUG ASSET + indication terms, phase = "PHASE3"
Keep the registrational trials; capture NCT, acronym, sponsor, status and enrollment verbatim.
2. EFFICACY. Call search_amass_biomedcore_records with:
query = the DRUG ASSET + indication terms, minJournalQualityJufo = 2, isRetracted = false
Pull 2–3 grounded findings; quote every number (%, mg, P, fibrosis stage) VERBATIM from the
abstract. Tag each with PMID, journal, JuFo tier, citationCount.
3. CROSS-CORE PROVENANCE. For the pivotal trial, call get_amass_trialcore_record and read its
referencesBiomedCore links — show NCT ↔ PMID, the publication↔trial edge.
4. Lay sections 1–3 out as a single-page .pdf snapshot: a regulatory-status callout, the trial
table, the grounded findings, and the provenance line. Close with a scope note — figures are
verbatim from Amass records as of <date>; this is an evidence digest, not regulatory advice.Why not just ask the model?
Ask a plain model for "a one-pager on resmetirom" and you get a confident page of unverifiable numbers — a fat-fraction here, an approval date there, a trial ID that won't resolve.
- Plain model: invents the hepatic-fat reduction, guesses the approval date, cites an NCT that doesn't resolve.
- Amass: −34.9% / −38.6% hepatic fat (PMID 37845512) · FDA accelerated approval, March 2024, F2–F3 fibrosis (PMID 38771485) · 56.6% vs 33.8% MASH resolution with weight loss (PMID 41127972) · NCT03900429 → PMID 41895606 — each figure copied from the record, not recalled.
Honest scope
A snapshot, not a dossier: two pivotal trials and a few grounded figures chosen to fit one page,
not a complete program or a meta-analysis. MAESTRO-NASH is still ACTIVE_NOT_RECRUITING (long-term
outcomes ongoing); every figure is verbatim from the cited abstract as of the run date and
traceable by the PMIDs and Amass IDs on the page. An evidence digest, not regulatory advice.
More showcases
Keep exploring
| rank | title | journal | publicationDate |
|---|---|---|---|
| 1 | Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico | The New England journal of medicine | 2022-02-10 |
| 2 | Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial | JAMA network open | 2023-04-03 |
| 3 | Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial | medRxiv (preprint) | 2022-09-21 |
Trial evidence trace
Paste one clinical-trial ID; get the exact published papers that describe it — pulled from Amass's publication↔trial graph, with trust metadata and abstract-grounded relevance notes.
1. Pivotal Phase-3 program
AMASS EVIDENCE BRIEF
Tirzepatide evidence brief
Name a drug asset; get a citation-auditable Word evidence brief — pivotal Phase-3 trials, grounded efficacy and safety findings, and the trial↔paper links — every figure verbatim from Amass.
EXPLORER-HCM - NCT03470545 (16 describing papers)
Submission Evidence Assembler - mavacamten (Camzyos)
Submission evidence assembler
Name one drug asset; get a citation-auditable, Module-2.5-style evidence narrative — every pivotal Phase-3 trial, its describing papers, and a canonical Amass-ID audit trail — assembled from Amass's publication↔trial graph with trust metadata on every cited paper.
Run it yourself
Connect Amass to Claude and paste the prompt.
No build, no deploy — the connector takes about a minute, then this workflow runs on your own inputs.